Natco Pharma wins key Risdiplam legal battle in India's Supreme Court

Natco Pharma Limited announced on October 17, 2025, that the Supreme Court of India dismissed a challenge by Swiss pharmaceutical company F. Hoffmann-La Roche AG in the Risdiplam suit. The court noted the concurrent findings of the Single Judge and Division Bench of the Delhi High Court, both denying injunctions against Natco Pharma. This decision marks the final challenge Roche could pose at the interim stage, allowing the suit to proceed to trial.

The legal victory means Natco Pharma can continue its operations related to Risdiplam without interim restrictions. Spinal Muscular Atrophy (SMA), which Risdiplam addresses, is a leading cause of infant mortality, and current treatment options are often financially prohibitive for Indian patients. This ruling is expected to offer hope for those affected by SMA.

Natco Pharma, headquartered in Hyderabad, India, develops, manufactures, and distributes pharmaceuticals including generics, specialty drugs, active pharmaceutical ingredients, and crop protection products. The company operates 9 manufacturing sites and 2 R&D facilities in India, with approvals from major regulatory authorities such as the US FDA and Brazil ANVISA, catering to over 50 global markets.